Get updates by email
Topics
Contributors
- David F. Hauge
- Sanford L. Michelman
- Alex Barnett-Howell
- Matthew R. Lasky
- Todd H. Stitt
- Mehmet Baysan
- Robert N. Berg
- Howard I. Camhi
- Ronald R. Camhi
- Stacey Chiu
- Christine Connell
- Jesse Contreras
- Seth E. Darmstadter
- Robert D. Estrin
- Jeffrey D. Farrow
- Taylor C. Foss
- Samantha Gavin
- John J. Giardino
- Kelly M. Hagemann
- Mona Z. Hanna
- Bradley Henry
- Ryan Hong
- Marc R. Jacobs
- Bryan Johnson
- Warren A. Koshofer
- Dana A. Kravetz
- Samuel M. Licker
- Vincent S. Loh
- Jennifer A. Mauri
- Amanda K. Monroe
- Megan J. Penick
- Michael S. Poster
- Richard Reice
- Mark B. Robinson
- Lara A. H. Shortz
- Eric Simonson
- Michael Smaila
- Adam Z. Solomon
- Peter L. Steinman
Archives
Contact
Paul Zimmerman
pzimmerman@mrllp.com
310.299.5500
Showing 3 posts by Jennifer A. Mauri.
arcady31 © 123RF.com
IP Deadlines and Fees Extended Under the CARES Act
The headlines coming out of the Coronavirus Aid, Relief, and Economic Security (CARES) Act becoming law have, in large part, been reserved for the financial relief, loans, and grants it provides for businesses and individuals nationwide. Lesser known, or reported, is the legislation’s impact on the intellectual property world. Yet to owners or would-be owners of IP, that aspect of the CARES Act is a big deal. (Read More)
wawritto © depositphotos.com
Attention Indie Musicians
Attention indie musicians: Rhapsody International Inc. has agreed to pay $10 million to resolve claims that they failed to pay songwriters royalties for their streamed music. What this means is that you may be entitled to compensation. (Read more)
studiom1 © 123RF.com
A Different Route: Challenging Orange Book Patents Via Inter Partes Review
Since the passage of the America Invents Act (AIA) in 2012, and the corresponding implementation of the inter partes review (IPR) process, patent challengers have been utilizing the Patent Trial and Appeal Board (PTAB) as an alternative venue for patent adjudication. The IPR process permits anyone other than the patent owner to challenge a patent's validity for alleged obviousness or lack of novelty based on patents or printed publications. This has become an increasingly popular avenue for challenging “orange book” pharmaceutical patents, many of which are simultaneously at issue in Hatch-Waxman / Abbreviated New Drug Application (ANDA) litigation in the federal courts. (Read More)